Valion Bio, Inc. has successfully entered into agreements to raise a total of $4.77 million through the sale of Series B and Series C preferred stocks. This funding is crucial for the company as it continues to develop its pharmaceutical offerings and compete in the evolving landscape of the pharmaceutical preparations industry.

On October 26, 2026, Valion Bio and 3i, LP finalized a deal under the Series B Preferred Purchase Agreement, allowing for the purchase of 50 Series B Non-Voting Convertible Preferred Shares and corresponding warrants. The total purchase price for this transaction amounts to $50,000. Additionally, the company has also secured agreements with certain purchasers for the sale of 4,717.73 Series C Preferred Shares and warrants, totaling approximately $4.72 million.

Background

Valion Bio, Inc. is a Delaware-based company operating in the pharmaceutical preparations sector, specifically focusing on developing innovative treatments and therapies. The company trades on the Nasdaq under the ticker symbol VBIO. Valion Bio has been actively engaged in raising capital to support its research and development initiatives, as evidenced by its recent filings.

What the Filing Says

The recent SEC filing details that Valion Bio and 3i entered into a letter agreement for the purchase of Series B Preferred Shares and warrants on October 26, 2026. The filing states, "3i agreed to purchase... 50 Series B Preferred Shares and Series B Warrants to purchase 1,539 shares of Common Stock for an aggregate purchase price of $50,000." Furthermore, the agreement with the Series C Preferred Purchasers includes the issuance of 4,717.73 Series C Preferred Shares and Series C Warrants for an aggregate purchase price of $4,717,717.61.

Impact

This funding is expected to enhance Valion Bio's financial stability and support its ongoing projects in the pharmaceutical sector. The agreements with 3i and other purchasers may positively influence the company's ability to innovate and expand its product offerings. Competitors in the pharmaceutical preparations industry will likely monitor Valion Bio's progress as it utilizes these funds to advance its research and development efforts.

What's Next

The filing does not say what happens next regarding the use of these funds or any upcoming corporate actions related to the newly issued preferred shares.